This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
McKesson (MCK) Earnings and Revenues Beat Estimates in Q2
by Zacks Equity Research
McKesson's (MCK) fiscal second-quarter 2022 results benefit from substantial growth in the Medical-Surgical Solutions business.
Hologic (HOLX) Q4 Earnings Surpass Estimates, 2022 View Dull
by Zacks Equity Research
Impressive performance by the Breast Health and GYN Surgical segments drives Hologic's (HOLX) fiscal fourth-quarter revenues.
NextGen Healthcare (NXGN) Gains 9.7% Since Q2 Earnings Beat
by Zacks Equity Research
NextGen Healthcare's (NXGN) fiscal second-quarter earnings reflect strong segmental performance.
Chemed (CHE) Q3 Earnings Beat Estimates, Full-Year EPS View Up
by Zacks Equity Research
Chemed (CHE) reports better-than-expected earnings and revenues in the third-quarter 2021, with a solid performance by the Roto-Rooter segment driving the top line.
OPKO Health's (OPK) Q3 Earnings, Revenues Top Estimates
by Zacks Equity Research
OPKO Health's (OPK) third-quarter results benefit from strength in its Pharmaceuticals segment, backed by robust RAYALDEE sales.
Integer Holdings (ITGR) Beats on Q3 Earnings, Ups 2021 EPS View
by Zacks Equity Research
Integer Holdings' (ITGR) third-quarter results reflect robust segmental performances along with strength in the majority of the product lines.
Merit Medical's (MMSI) Q3 Earnings, Revenues Top Estimates
by Zacks Equity Research
Merit Medical (MMSI), in the third quarter, benefits from revenue growth in its Cardiovascular segment, and from the majority of the product categories within its Cardiovascular unit.
Cerner (CERN) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Cerner's (CERN) third-quarter results benefit from gains across four of its business units.
Bio-Rad (BIO) Q3 Earnings Surpass Estimates, 2021 View Raised
by Zacks Equity Research
Strength in the Life Science and Clinical Diagnostics segments drove Bio-Rad's (BIO) revenues in the third quarter.
DexCom (DXCM) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
DexCom's (DXCM) third-quarter results benefit from domestic and international revenue growth and solid new customer additions.
Stryker (SYK) Earnings and Revenues Miss Estimates in Q3
by Zacks Equity Research
Despite pandemic-led disruptions, Stryker's (SYK) third-quarter earnings reflect strong performance across Orthopaedics, MedSurg and Neurotechnology and Spine segments.
ResMed (RMD) Q1 Earnings Top Estimates, Margins Decline
by Zacks Equity Research
ResMed (RMD) reports better-than-expected earnings and revenues with robust demand for sleep and respiratory care devices driving Q1 top line.
DaVita (DVA) Beats on Q3 Earnings, Narrows 2021 EPS View
by Zacks Equity Research
DaVita's (DVA) strength in dialysis patient service revenues drives its Q3 top line.
Teleflex (TFX) Q3 Earnings Top Estimates, Full-Year EPS View Up
by Zacks Equity Research
Teleflex (TFX) reports better-than-expected earnings and revenues with strong geographical performance driving the top line in third-quarter 2021.
West Pharmaceutical (WST) Q3 Earnings & Revenues Beat Estimates
by Zacks Equity Research
West Pharmaceutical's (WST) third-quarter earnings reflect segmental strong performance.
West Pharmaceutical Services (WST) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
West Pharmaceutical (WST) delivered earnings and revenue surprises of 13.19% and 3.18%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for West Pharmaceutical Services (WST) This Earnings Season?
by Zacks Equity Research
West Pharmaceutical Services (WST) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
BD (BDX) Gears Up for Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Continued strength in BD's (BDX) Life Sciences and Interventional segments is expected to have driven up Q4 sales.
What's in Store for Henry Schein (HSIC) in Q3 Earnings?
by Zacks Equity Research
Strengthening demand in the global dental and medical markets along with the recent investments are likely to have contributed to Henry Schein's (HSIC) Q3 performance.
SmileDirectClub (SDC) Introduces Two New Water Flossers
by Zacks Equity Research
SmileDirectClub (SDC) launched the new Large Tank and Compact Water Flossers, currently available at Shop.SmileDirectClub.com, Amazon, Walmart and Walmart.com.
Breast Health Sales to Drive Hologic's (HOLX) Q4 Earnings
by Zacks Equity Research
The acquisition of Biotheranostics and the launch of new software are expected to have contributed to Hologic's (HOLX) Breast Health arm performance in the fourth quarter.
Catalent (CTLT) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Catalent's (CTLT) Biologics segment is likely to have maintained its momentum, thereby aiding Q1 results.
Hologic (HOLX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Hologic's (HOLX) recent acquisitions and product launches are expected to contribute significantly to its fourth-quarter performance.
QIAGEN's (QGEN) New Manchester Facility to Fortify UK Foothold
by Zacks Equity Research
QIAGEN's (QGEN) new campus is expected to bring the benefits of transformational molecular diagnostics to Manchester and the global healthcare market.
PDCO vs. WST: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PDCO vs. WST: Which Stock Is the Better Value Option?